Verenigde Staten - Engels - NLM (National Library of Medicine)

avkare, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 5 mg - ramipril capsules, usp are indicated for the treatment of hypertension. they may be used alone or in combination with thiazide diuretics. ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy categories c (first trimester) and d (second and third trimesters) [ see warnings and precautions ( 5.6 ) ]. ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in u.s. clinical

Verenigde Staten - Engels - NLM (National Library of Medicine)

zydus lifesciences limited - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with diffe

Verenigde Staten - Engels - NLM (National Library of Medicine)

zydus lifesciences limited - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that ramipril does not have a similar risk (see warnings). in considering use of ramipril, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings, angioedema). ramipril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril -

Verenigde Staten - Engels - NLM (National Library of Medicine)

invagen pharmaceuticals, inc - ramipril (unii: l35jn3i7sj) (ramipril - unii:l35jn3i7sj) - capsule - 1.25 mg - ramipril is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that ramipril does not have a similar risk. (see warnings. ) in considering use of ramipril, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see warnings, angioedema. ) ramipril is contraindicated in patients who are hypersensitive to this product or any other angiotensin converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ramipril -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ramipril -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ramipril -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ramipril -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - ramipril -